` NYR (Nyrada Inc) vs S&P/ASX 300 Comparison - Alpha Spread

NYR
vs
S
S&P/ASX 300

Over the past 12 months, NYR has significantly outperformed S&P/ASX 300, delivering a return of +774% compared to the S&P/ASX 300's +7% growth.

Stocks Performance
NYR vs S&P/ASX 300

Loading
NYR
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NYR vs S&P/ASX 300

Loading
NYR
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
NYR vs S&P/ASX 300

Loading
NYR
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Nyrada Inc vs Peers

S&P/ASX 300
NYR
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Nyrada Inc
Glance View

Market Cap
175.1m AUD
Industry
Pharmaceuticals

Nyrada, Inc. operates as a pre-clinical stage, drug development company. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. The company is also developing new therapies.

NYR Intrinsic Value
0.07 AUD
Overvaluation 92%
Intrinsic Value
Price
Back to Top